by wallyg

& ITS TREATMENT WITH MALINGNANT glioma chemotherapeutic agents – temozolomide

& ITS TREATMENT WITH MALINGNANT glioma chemotherapeutic agents â? Temozolomide

Free Online Articles Directory

Why Submit Articles?
Top Authors
Top Articles
FAQ
ABAnswers

Publish Article

0 & & $. Browser.msie) {
var ie_version = parseInt ($ browser.version.)
if (ie_version Login

Login via

Register
Hello
My Home
Sign Out

Email

Password


Remember me?
Lost Password?

Home Page > Health > Medicine > & ITS TREATMENT WITH MALINGNANT glioma chemotherapeutic agents â? Temozolomide

& ITS TREATMENT WITH MALINGNANT glioma chemotherapeutic agents â? Temozolomide

Edit Article |

Posted: Aug 11, 2009 | Comments: 0
| Views: 109 |

INTRODUCTION

Malignant gliomas (anaplastic astrocytoma and glioblastoma multiforme) Occur more frequently than other types of primary CNS tumors, having a combined incidence of 5â? 8 / 100, 000 population. Even with aggressive treatment using surgery, radiation, and chemotherapy, median survival is reported less than 1 yearÂ. Temozolomide, a new drug, has shown promise in treating malignant gliomas and other difficult-to-treat tumors. Temozolomide represents a new class of second-generation prodrugs that undergo spontaneous conversion imidazotetrazine under physiological conditions to the active alkylating agent MTIC. Thus, temozolomide does not require hepatic metabolism for activationÂ.

Interest in anti-tumor agent temozolomide as to derive from its broad-spectrum anti-tumor activity in tumor models in miceÂ. In vitro, temozolomide has Demonstrated schedule-dependent antitumor activity against a variety of malignancies, including glioma, metastatic melanoma, and other difficult-to-treat cancers. In preclinical studies, temozolomide Demonstrated distribution to all tissues, including penetration into the CNS; Relatively low toxicity compared with its parent compound, mitozolomide, and anti-tumor activity against a broad range of tumor types, including glioma, melanoma, mesothelioma, sarcoma, lymphoma, leukemia, and carcinoma of the colon and ovary. Demonstrated ability to tumors Its cross the blood-brain barrier is of special interest with respect to its activity in CNS.

In Phase 1 and 2 clinical studies conducted by the CRC (London, United Kingdom), temozolomide was absorbed rapidly, exhibited 100% po bioavailability within 1â? 2 h of administration, and Demonstrated antineoplastic activity in recurrent high-grade glioma, melanoma, fungoides and mycosis. Results of these trials showed that when temozolomide is administered po once daily for 5 days in a 4-week cycle, it is well tolerated, producing mild-to-moderate toxicity that is both predictable and easily managed. The results thus confirmed the ability of temozolomide to penetrate the CNS and has indicated that temozolomide Considerable potential in treating gliomas and improving the QOL of patients with glioma. Additional phase 1 studies have confirmed these results and have extended these observations to pediatric patients.

Temozolomide has been evaluated in a number of Phase 2 and 3 clinical trials for the treatment of glioblastoma multiforme, anaplastic astrocytoma, and malignant metastatic melanomaâ? Malignancies For Which there are no satisfactory therapies. On the basis of the results of these studies, temozolomide has been approved in the European Union for the treatment of patients with glioblastoma multiforme showing progression or recurrence after standard therapy. Recently, temozolomide received accelerated approval from the FDA for treatment of adult patients with anaplastic astrocytoma who have relapsed after treatment that included a nitrosurea drug (BCNU or CCNU) and procarbazine. Studies are under way to evaluate the combination of temozolomide with other chemotherapeutic agents and biochemotherapy in the treatment of malignant glioma and metastatic melanoma, respectively. This article reviews the mechanism of action of temozolomide as an anti cancer agent and summarize the most recent clinical studies of temozolomide for the treatment of malignant gliomas.

REFERENCES

Avgeropoulos NG, Batchelor TT New treatment strategies for malignant gliomas. Oncologist, 4: 209-224, 1999. Clark AS, Deans B, Stevens MF, Tisdale MJ, Wheelhouse RT, Denny BJ, Hartley JA imidazotetrazines anti-tumor. 32. Synthesis of Novel Bicyclic imidazotetrazinones and related heterocycles to probe the mode of action of the antitumor drug temozolomide. J. Med Chem, 38. 1493-1504, 1995. Stevens MFG, Hickman JA, Langdon SP, Chubb D, Vickers L., Stone R., Baig G, Goddard C., Gibson NW, Slack JA, Newton C., Lunt E., Fizames C., Lavelle F. antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methylimidazo [5,1-d] -1,2,3,5-tetrazine-4 (3H)-one (CCRG 81 045: M & B39831), a novel drug with potential as on alternative to dacarbazine. Cancer Res 47: 5846-5852, 1987. Friedman HS, Dolan ME, Pegg AE, Marcelli S., Keir S., Catino JJ, Bigner DD, Scholder SC, Jr. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res, 55: 2853-2857, 1995. Plowman J, Waud WR, Koutsoukos AD, Rubinstein LV, Moore TD, Grever MR Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis (2-chloroethyl)-1-nitrosourea. Cancer Res 54: 3793-3799, 1994. Pera MF, KÃ ¶ berle B., Masters JRW Exceptional sensitivity of testicular germ cell tumor cell lines to the new anti-cancer agent temozolomide. Br J Cancer, 71: 904-906, 1995. Carter CA, Waud WR, Plowman J. Responses of human melanoma, ovarian, and colon tumor xenografts in nude mice to oral temozolomide. Proc. Am. Assoc. Cancer Res, 35: 297 1994th Wedge SR, Porteous JK, Newlands ES Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model. Cancer Chemother. Pharmacol, 40:. 266-272, 1997. Patel M, McCully C, Godwin K., Balis F. Plasma and cerebrospinal fluid pharmacokinetics of temozolomide. Proc. Am. Soc. Clin. Oncol, 14:. 461 1995th

10.A Newlands ES, Blackledge GRP, Slack JA, Rustin GJS, Smith DB, Stuart NSA, Quarterman CP, Hoffman R., Stevens MFG, Brampton MH, Gibson AC Phase I trial of temozolomide (CCRG 81045: M & B 39 831: NSC 362 856 ). Br J Cancer, 65: 287-291, 1992.

11.A Bleeh NM, Newlands ES, Lee SM, Thatcher N., Selby P., Calvert AH, Rustin GJS, Brampton M., Stevens MFG Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J. Clin. Oncol, 13:. 910-913, 1995.

12.A Oâ Reilly SM, Newlands ES, Glaser MG, Brampton M., Rice-Edwards JM, Illingworth RD, Richards PG, Kennard C., Colquhoun IR, Lewis P., Stevens MFG Temozolomide:? A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumors. Eur J Cancer, 29A: 940-942, 1993.

13.a Bower M., Newlands ES, Bleeh NM, Brada M., Begent RJH, Calvert H., Colquhoun I., Lewis P., Brampton MH Multicentre CRC Phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother. Pharmacol, 40:. 484-488, 1997.

14.A Paulsen F, Hoffmann W., Becker G, Belka C, Weinmann M, Classen J, Kortmann RD, Bamberg M. Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide. J. Cancer Res Clin. Oncol, 125. 411-418, 1999.

15.a Estlin EJ, Lashford L., Ablett S, Price L, Gowing R, Gholkar A., J. Kohler, Lewis IJ, Morland B, Pinkerton CR, Stevens MCG, Mott M, Stevens R. , Newell DR, Walker D, Dicks-Mireaux C., McDowell H, Reidenberg P., P. Statkevich, Marco A., Batra V, Dugan M, Pearson ADJ Phase I study of temozolomide in pediatric patients with advanced cancer. United Kingdom Childrenâ € ™ s Cancer Study Group. Br J Cancer, 78: 652-661, 1998.

16.a Nicholson HS, Krailo M., Ames MM, Seibel NL, Reid JM, Liu-Mares W, Vezina LG, Ettinger AG, Reaman GH Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from The Childrenâ € ™ s Cancer Group. J. Clin. Oncol, 16:. 3037-3043, 1998.

17.A Stevens MFG, Hickman JA, Stone R., Gibson NW, Baig GU, Lunt E, Newton CG imidazotetrazines anti-tumor. 1. Synthesis and Chemistry of 8-carbamoyl-3-(2-chloroethyl) imidazo [5,1-d] -1,2,3,5-tetrazine-4 (3H)-one, a novel broad-spectrum anti-tumor agent. J. Med Chem, 27:. 196-201, 1984.

18.A Hickman JA, Stevens MFG, Gibson NW, Langdon SP, Fizames C., Lavelle F., Atassi G, Lunt E, Tilson RM Experimental antitumor activity against murine tumor model systems of 8-carbamoyl-3-(2 -chloroethyl) imidazo [5,1-d] -1,2,3,5-tetrazine-4 (3H)-one (mitozolomide), a novel broad-spectrum agent. Cancer Res 45: 3008-3013, 1985.

19.A Horgan CMT, Tisdale MJ An investigation into the mechanism of antitumour activity of a novel and potent antitumour agent, mitozolomide (CCRG 81 010, M & B 39 565, NSC 353 451). Biochem. Pharmacol, 33:. 2185-2192, 1984.

20.A Gibson NW, Hickman JA, Erickson LC DNA cross-linking and cytotoxicity in normal and transformed human cells treated in vitro with 8-carbamoyl-3-(2-chloroethyl) imidazo [5,1-d] -1,2 ,3,5-tetrazine-4 (3H)-one. Cancer Res, 44: 1772-1775, 1984.

21.A Gibson NW, Erickson LC, Hickman JA Effects of the antitumor agent 8-carbamoyl-3-(2-chloroethyl) imidaz [5,1-d] -1,2,3,5-tetrazine-4 (3H) -one on the DNA of mouse L1210 cells. Cancer Res, 44: 1767-1771, 1984.

22.a Horgan CMT, Tisdale MJ Uptake and decomposition of a novel antitumour agent mitozolomide (CCRG 81 010, M and B 39 565, NSC 353 451) in mouse lymphoma TLX5 in vitro. Biochem. Pharmacol, 34:. 217-221, 1985.

23.A VL Bull, MJ Tisdale antitumour imidazotetrazines-XVI macromolecular alkylation by 3-substituted imidazotetrazinones. Biochem. Pharmacol, 36:. 3215-3220, 1987.

24.A Newlands ES, Blackledge G, Slack JA, Goddard C, Brindley CJ, Holden L, Stevens MFG Phase I clinical trial of mitozolomide. Cancer Treat. Rep., 69: 801-805, 1985.

25.A Stevens MF, Newlands ES From triazines and triazenes to temozolomide. Eur J Cancer, 29A: 1045-1047, 1993.

26.A Clark AS, Stevens MFG, Sansom CE, Schwalbe CH anti-tumor imidazotetrazines. Part XXI. Mitozolomide and temozolomide: probes for the major groove of DNA. Anticancer Drug Des, 5. 63-68, 1990.

27.a Lowe PR, Sansom CE, Schwalbe CH, Stevens MFG, Clark AS imidazotetrazines anti-tumor. 25. Crystal structure of 8-carbamoyl-3-methylimidazo [5,1-d] -1,2,3,5-tetrazine-4 (3H)-one (temozolomide) and structural comparisons with the related drugs mitozolomide and DTIC. J. Med Chem, 35. 3377-3382, 1992.

28.A Spassova MK, Golovinsky EV Pharmacobiochemistry of arylalkyltriazenes and their application in cancer chemotherapy. Pharmacol. There, 27:. 333-352, 1985.

29. Denny BJ, Wheelhouse RT, Stevens MFG, Tsang LLH, Slack JA NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry, 33: 9045-9051, 1994.

30. Liu L., Taverna P., Whitacre CM, Chatterjee S., Gerson SL pharmacologic disruption of base excision repair sensitize mismatch repair-deficient and-proficient colon cancer cells to methylating agents. Clin. Cancer Res, 5: 2908-2917, 1999.

31. Catapano CV, Broggini M., Erba E., Ponti M., L. Mariani, L. Citti, DA? Incalci M. In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas. Cancer Res 47: 4884-4889, 1987.

32. B. Deans, Tisdale MJ antitumour imidazotetrazines XXVIII 3-methyladenine DNA glycosylase activity in cell lines sensitive and resistant to temozolomide. Cancer Lett, 63. 151-157, 1992.

33. Wedge SR, Porteous JK, Newlands ES 3-aminobenzamide and / or O6-benzylguanine evaluated as adjuvant to temozolomide or BCNU in treatment in cell lines of variable mismatch repair status and O6-alkylguanineâ? DNA alkyltransferase activity. Br J Cancer, 74: 1030-1036, 1996.

34.A Wedge SR, Porteus JK, May BL, Newlands ES Potentiation of temozolomide and BCNU cytotoxicity by O6-benzylguanine: a comparative study in vitro. Br J Cancer, 73: 482-490, 1996.

35. Dolan ME, Mitchell RB, Mummert C, Moschel RC, Pegg AE Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res 51: 3367-3372, 1991.

36. Dolan ME, Moschel RC, Pegg AE Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc. Natl. Acad. Sci. USA, 87: 5368-5372, 1990.

Since 37.Â? Atri S., Piccioni D., Castellano A., Tuorto V., A. Franchi, K. Lu, N. Christiansen, S. Frankel, Rustum YM, Papa G, Mandelli F., Bonmassar E. Chemosensitivity to triazenes compounds and O6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients. Ann. Oncol, 6:. 389-393, 1995.

38. Drummond JT, Li GM, Longley MJ, Modrich P. Isolation of an hMSH2â? P160 heterodimer that restores DNA mismatch repair to tumor cells. Science (Washington, DC), 268: 1909-1912, 1995.

39. Palombo F., Gallinari P., Iaccarino I., Lettieri T., Hughes M., DA? Arrigo A., Truong O., Hsuan JJ, Jiricny J. GTBP, a 160-kilodalton protein essential for mismatch -binding activity in human cells. Science (Washington, DC), 268: 1912-1914, 1995.

40. Li GM, Modrich P. Restoration of mismatch repair to nuclear extracts of H6 colorectal tumor cells by a heterodimer of human MutL homologs. Proc. Am. Assoc. Cancer Res, 92: 1950-1954, 1995.

41. Karran P, Macpherson P, Ceccotti S, Dogliotti E, Griffin S, Bignami M. O6-methylguanine residues elicit DNA repair synthesis by human cell extracts. J. Biol Chem, 268:. 15878-15886, 1993.

42. Taverna P., Catapano CV, Citti L., M. Bonfanti, DA? Incalci M. Influence of O6-methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse leukemia sensitive and resistant to chloroethylnitrosoureas. Anticancer Drugs, 3: 401-405, 1992.

43. Karran P., Hampson R. Genomic instability and tolerance to alkylating agents. Cancer Surv, 28:. 69-85, 1996.

44. Karran P., Bignami M. Self-destruction and tolerance in resistance of mammalian cells to alkylation damage. Nucleic Acids Res 20: 2933-2940, 1992.

45. Tentori L., Graziani G, Gilberti S, Lacal PM, Bonmassar E., DA? Atri S. triazenes compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines. Leukemia, 9: 1888-1895, 1995.

46. Bianchi R., Citti L., Beghetti R., L. Romani, DA? Incalci M., P. Puccetti, MC Fioretti O6-Methylguanine-DNA methyltransferase activity and induction of novel immunogenicity in murine tumor cells treated with methylating agents. Cancer Chemother. Pharmacol, 29:. 277-282, 1992.

47. Allegrucci M., Fuschiotti P., P. Puccetti, L. Romani, MC Fioretti Changes in the tumorigenic and metastatic properties of murine melanoma cells treated with a derivative triazenes. Clin. Exp Metastasis, 7: 329-341, 1989.

48. L. Tentori, C. Leonetti, Aquino A. Temozolomide Reduces the metastatic potential of Lewis lung carcinoma (3LL) in mice: role of -6 integrin phosphorylation. Eur J Cancer, 31A: 746-754, 1995.

49. Tisdale MJ antitumour imidazotetrazinesâ? XVIII. Modification of the level of 5-methylcytosine in DNA by 3-substituted imidazotetrazinones. Biochem. Pharmacol, 38:. 1097-1101, 1989.

50.a PA Hepburn, MJ Tisdale Growth suppression by DNA from cells treated with imidazotetrazinones. Biochem. Pharmacol, 41:. 339-343, 1991.

51. Zucchetti M., Catapano CV, Filippeschi S., Erba E., DA? Incalci M. Temozolomide induced differentiation of K562 leukemia cells is not mediated by gene hypomethylation. Biochem. Pharmacol, 38:. 2069-2075, 1989.

52. Pegg AE, Dolan ME, Moschel RC Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 51: 167-223, 1995.

Since 53.Â? Incalci M., Citti L., Taverna P., Catapano CV Importance of the DNA repair enzyme O6-alkyl guanine alkyltransferase (AT) in cancer chemotherapy. Cancer Treat. Rev., 15: 279-292, 1988.

54. Pegg AE, Byers TL Repair of DNA containing O6-alkylguanine. FASEB J., 6: 2302-2310, 1992.

55.A Tisdale MJ Antitumor imidazotetrazinesâ? XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem. Pharmacol, 36:. 457-462, 1987.

56. Baer JC, Freeman AA, Newlands ES, Watson AJ, Rafferty JA, Margison GP Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumor cells. Br J Cancer, 67: 1299-1302, 1993.

57. Redmond SM, Joncourt F., Buser K, Ziemiecki A, Altermatt HJ, Fey M, Margison G, Cerny T. Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors. Cancer Res 51: 2092-2097, 1991.

58. Franchi A., G. Papa, DA Atri S., Piccioni D., Masi M., Bonmassar E. Cytotoxic effects of dacarbazine in patients with acute myelogenous leukemia?? A pilot study. Haematologica, 77: 146-150, 1992.

59. Wang G., Weiss C, Sheng P, Bresnick E. Retrovirus-mediated transfer of the human O6-methylguanine-DNA methyltransferase gene into a murine hematopoietic stem cell line and resistance to the toxic effects of certain alkylating agents. Biochem. Pharmacol, 51. 1221-1228, 1996.

60. Walker MC, Masters JRW, Margison GP O6-alkylguanine-DNA alkyltransferase activity and nitrosourea sensitivity in human cancer cell lines. Br J Cancer, 66: 840-843, 1992.

61. Bobola MS, Tseng SH, Blank A., Berger MS, Silver JR Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. Clin. Cancer Res, 2: 735-741, 1996.

62. Liu L., Markowitz S., Gerson SL Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis (2-chloroethyl) nitrosourea. Cancer Res 56: 5375-5379, 1996.

63. Friedman HS, Johnson SP, Dong Q., Scholder SC, Rasheed BKA, Bigner SH, Ali-Osman F., Dolan E., Colvin OM, Houghton P, Germain G, Drummond JT, Keir S., Marcelli S., Bigner DD, Modrich P. methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res, 57: 2933-2936, 1997.

64. Tisdale MJ antitumour imidazotetrazines-XI: effect of 8-carbamoyl-3-methylimidazo [5,1-d] -1,2,3,5-tetrazine-4 (3H)-one [CCRG 81 045, M and B 362 856 39 831 NSC] on poly (ADP-ribose) metabolism. Br J Cancer, 52: 789-792, 1985.

65. Durkacz BW, Omidiji O., Gray DA, Shall S. (ADP-ribose) n Participates in DNA excision repair. Nature (Lond.), 283: 593-596, 1980.

66. Boulton S., Pemberton LC, Porteous JK, Curtin NJ, Griffin RJ, Golding BT, BW Potentiation of temozolomide Durkacz-induced cytotoxicity: a comparative study of the biological effects of poly (ADP-ribose) polymerase inhibitors. Br J Cancer, 72: 849-856, 1995.

67. Z. Wu, Chan CL, Eastman A., Bresnick E. Expression of human O6-methylguanine-DNA methyltransferase in Chinese hamster ovary cells and restoration of cellular resistance to certain N-nitroso compounds. Mol Carcinogen, 4. 482-488, 1991.

68. Tentori L., Turriziani M., Franco D., Serafino A., Levati L., Roy R., Bonmassar E., Graziani G. Treatment with temozolomide and poly (ADP-ribose) polymerase inhibitors induces early apoptosis and Increases base excision repair gene transcripts in leukemic cells resistant to triazenes compounds. Leukemia, 13: 901-909, 1999.

69. Imperatori L., Damia G., P. Taverna, E. Garattini, L. Citti, L. Boldrini, DA? Incalci M. NIH 3T3 murine fibroblasts and B78 murine melanoma cells expressing the Escherichia coli N3-methyladenine- DNA glycosylase I do not become resistant to alkylating agents. Carcinogenesis (Lond.), 15: 533-537, 1994.

70. Friedman HS, Dolan ME, Moschel RC, Pegg AE, Felker GM, Rich J., Bigner DD, Enhancement of nitrosourea activity Scholder SCJ in medulloblastoma and glioblastoma multiforme. J. Natl. Cancer Inst, 84: 1926-1931, 1992.

71. Dolan ME, Pegg AE O6-benzylguanine and its role in chemotherapy. Clin. Cancer Res, 3: 837-847, 1997.

72. Middleton MR, Kelly J, Thatcher N, Donnelly DJ, McElhinney RS, McMurry TB, McCormick JE, Margison GP O6-(4-bromothenyl) guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts. Int. J. Cancer, 85: 248-252, 2000.

73. Wedge SR, Newlands ES O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. Br J Cancer, 73: 1049-1052, 1996.

74. Fairbairn LJ, Watson AJ, Rafferty JA, Elder RH, Margison GP O6-benzylguanine Increases the sensitivity of human primary bone marrow cells to the cytotoxic effects of temozolomide. Exp Hematol, 23:. 112-116, 1995.

75. Chinnasamy N., Rafferty JA, Hickson I., Ashby J., Tinwell H., Margison GP, Dexter TM, Fairbairn LJ O6-benzylguanine potentiate the in vivo toxicity and clastogenicity of temozolomide and BCNU in mouse bone marrow. Blood, 89: 1566-1573, 1997.

76. Chinnasamy N., Rafferty J., L. Lashford, Chinnasamy D., Margison G., Thatcher N., Dexter T., Fairbairn L. Protection of committed murine haemopoietic progenitors against BCNU toxicity does not predict protection of primitive, multipotent spleen colony-forming cellsâ? implications for chemoprotective gene therapy. Leukemia, 13: 1776-1783, 1999.

77. Reese JS, Davis BM, Liu L., Gerson SL Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide. Clin. Cancer Res, 5: 163-169, 1999.

78. Chinnasamy N., Rafferty JA, Hickson I., Lashford LS, Longhurst SJ, Thatcher N., Margison GP, Dexter TM, Fairbairn LJ chemoprotective gene transfer II: multilineage in vivo protection of haemopoiesis against the effects of an antitumour agent by expression of a mutant human O6-alkylguanine-DNA alkyltransferase. Gene There, 5:. 842-847, 1998.

79. Hickson I, Fairbairn LJ, Chinnasamy N., Lashford LS, Thatcher N., Margison GP, Dexter TM, Rafferty JA chemoprotective gene transfer I: transduction of human haemopoietic progenitors with O6-benzylguanine-resistant O6-alkylguanine-DNA alkyltransferase attenuates the toxic effects of O6-alkylating agents in vitro. Gene There, 5:. 835-841, 1998th

80. Hammond LA, Eckardt JR, Baker SD, Eckhardt SG, Dugan M., Forral K., Reidenberg P., Statkevich P., Weiss GR, Rinaldi DA, Von Hoff DD, Rowinsky EK Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J. Clin. Oncol, 17:. 2604 1999th

81. Brock CS, Newlands ES, Wedge SR, Bower M., Evans H., Colquhoun I., Roddie M., Glaser M, Brampton MH, Rustin GJS Phase I trial of temozolomide using for extended continuous oral schedule. Cancer Res, 58: 4363-4367, 1998.

82. Baker SD, Wirth M., Statkevich P., Reidenberg P., Alton K., Sartorius SE, Dugan M., Cutler D., Batra V., Grochow LB, Donehower RC, Rowinsky EK Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin. Cancer Res, 5: 309-317, 1999.

83. Dhodapkar M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC, Ames MM, Suman VJ Phase I trial of temozolomide (NSC 362 856) in patients with advanced cancer. Clin. Cancer Res, 3: 1093-1100, 1997.

84. Brada M, Judson I, Beale P, Moore S, Reidenberg P., Statkevich P., Dugan M, Batra V, Cutler D. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52 365) for refractory or relapsing malignancies. Br J Cancer, 81: 1022-1030, 1999.

85. P. Beale, I. Judson, S. Moore, P. Statkevich, Marco A., Cutler DL, Reidenberg P., Brada M. Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide. Cancer Chemother. Pharmacol, 44:. 389-394, 1999.

86. Feun LG, Savaraj N., Landy HJ Drug resistance in brain tumors. J. Neurooncol, 20:. 165-176, 1994.

87. Prados MD, Russo C. Chemotherapy of brain tumors. Semin. Surg. Oncol, 14:. 88-95, 1998.

88. Pech IV, Peterson K, Cairncross JG Chemotherapy for brain tumors. Oncology, 12: 537-553, 1998

89. Rodriguez LA, Levin VA Does chemotherapy benefit the patient with a central nervous system glioma? [See comments]. Oncology (Huntingt), 1: 29-36, 1987.

90. Newlands ES, Oâ? Reilly SM, Glaser MG, Bower M., Evans H, Brock C, Brampton MH, Colquhoun I., Lewis P., Rice Edwards JM, Illingworth RD, Richards PG The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer, 32A: 2236-2241, 1996.

91. Yung A., Levin VA, Albright R, Olson J, Fredericks R, Fink K, Prados M, Brada M, Spence A., Bruner J., Yue N., Dugan MH Zaknoen, S., Temodal Brain Tumor Group. Randomized trial of Temodal (TEM) Vs. procarbazine (PCB) in glioblastoma multiforme (GBM) at first relapse. Proc. Am. Soc. Clin. Oncol, 18:. 139 1999th

92. Yung WK, Prados MD, Yaya-Tur R., Rosenfeld SS, Brada M., Friedman HS, Albright R, Olson J, Chang SM, Oâ? Neill AM, Friedman AH, Bruner J., Yue N., Dugan M., Zaknoen S., Levin VA Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J. Clin. Oncol, 17:. 2762 1999th

93.  Friedman HS, McLendon RE, Kerby T., Dugan M., Bigner SH, Henry AJ, Ashley DM, Krischer J., Lovell S., Rasheed K., Marchev F., Seman AJ, Cokgor I. Rich J., Stewart E., Colvin OM, Provenzale JM, Bigner DD, Haglund MM, Friedman AH, Modrich PL DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J. Clin. Oncol, 16:. 3851-3857, 1998.

Retrieved from " http://www.articlesbase.com/medicine-articles/malingnant-gliomas-its-treatment-with-chemotherapeutic-agent-temozolomide-1117213.html "

(ArticlesBase SC # 1117213)

Watch your traffic increase just by submitting articles with us, click here to get started.
Liked this article? Click here to publish it on your website or blog, it's free and easy!

narendrakolla –
About the Author:

Questions and Answers

Ask our experts your Medicine related questions here …

Ask

200 Characters left

Who is at risk for malignant melanoma?

Rate this Article

1
2
3
4
5

vote (s)
0 vote (s)

Feedback
RSS
Print
Email
Re-Publish

Source: http://www.articlesbase.com/medicine-articles/malingnant-gliomas-its-treatment-with-chemotherapeutic-agent-temozolomide-1117213.html

Article Tags:
temozolomide , MTIC , malignant gliomas , metastatic malignant melanoma

Related Videos

Latest Medicine Articles

What are gliomas

Mark P. Atlas MD, Hematology Schneider Childrenâ ™ s Hospital DrMDK (01:33)

Orlistat online

Xenical is a prescription medicine that helps you Which to lose your weight.

By:
Medical Info l

Health >
Medicine l
Mar 04, 2011

Allegra drug

Allegra is a prescription medicine used for Which is the treatment of seasonal allergies.

By:
Medical Info l

Health >
Medicine l
Mar 04, 2011

Differin gel

Differin is a prescription medicine used to treat acne Which is. It helps in reducing the numbers of pimples and then heal from the pimple That Do develop.

By:
Medical Info l

Health >
Medicine l
Mar 04, 2011

Xenical drug

Xenical is a prescription medicine used for Which is the treatment of obesity.

By:
Medical Info l

Health >
Medicine l
Mar 04, 2011

Information on Bulimia Treatment

Bulimia can be caused due to various factors in a person's life. These factors might be psychological, biological, societal pressures to look thin, family of the individual, any traumatic event and media pressure to look a Particular Way.

By:
Brett Fuller l

Health >
Medicine l
Mar 04, 2011

More proof that Zinc Fights the Common Cold

One of the most effective alternative cures for the common cold has long been thought to be zinc. Many studies have in the past allured to its potential power in battling the frustrating, recurring illness.

By:
Jeff Jurmain l

Health >
Medicine l
Mar 04, 2011

Medicine Used For The Treatment Of Dry Eyes in Dogs

Optimmune is a prescription medicine used in dogs Which is for the treatment of dry eyes in dogs. It is therefore reffered to keratoconjunctivitis sicca. It is a mmunosuppressive agent Which is used to treat inflammation in the eyes.

By:
Robet Morkal l

Health >
Medicine l
Mar 04, 2011

Are You Suffering From High Blood Pressure?

Valsartan is that drugs Which belongs to the angiotensin II inhibitor class of medicine. It is a prescription medicine used for Which is the treatment of high blood pressure and hypertension.

By:
Robet Morkal l

Health >
Medicine l
Mar 04, 2011

Add new Comment

Your Name: *

Your Email:

Comment Body: *

Verification code: *

* Required fields

Submit

Your Articles Here
It's Free and Easy

Sign Up Today

Author Navigation

My Home
Publish Article
View / Edit Articles
View / Edit Q & A
Edit your Account
Manage Authors
Statistics Page
Personal RSS Builder
My Home
Edit your Account
Update Profile
View / Edit Q & A
Publish Article
Author Box

narendrakolla has 1 article online

Contact Author

Subscribe to RSS

Print article

Send to friend

Re-Publish article

Articles Categories
All Categories

Advertising
Arts & Entertainment
Automotive
Beauty
Business
Careers
Computers
Education
Finance
Food and Beverage
Health
Hobbies
Home and Family
Home Improvement
Internet
Law
Marketing
News and Society
Relationships
Self Improvement
Shopping
Spirituality
Sports and Fitness
Technology
Travel
Writing

Health

Acne
Allergies
Alternative Medicine
Anti Aging
Cancer
Dental Care
Disabilities
Diseases and Conditions
Hair Loss
Hearing
Medical Tourism
Medicine
Men's Health
Mental Health
Nutrition
Plastic Surgeries
Quit Smoking
Sleep
Supplements & Vitamins
Vision
Wellness
Women's Health

Need Help?
Contact Us
FAQ
Submit Articles
Editorial Guidelines
Blog

Site Links

No related posts.

Related posts brought to you by Yet Another Related Posts Plugin.